Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24628664 | 0.85 | APP (0.45) | CYP11B1CYP11B2NQO1 | |
| SCHEMBL30108653 | 0.85 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL28934574 | 0.85 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL3819558 | 0.84 | CYP11B1 (0.51) | CHRNB2CHRNA4CYP11B1CYP11B2CHRNB4 | |
| SCHEMBL188863 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL7924171 | 0.82 | MAPT (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL1557490 | 0.81 | GGPS1 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL19668758 | 0.81 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL17686148 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL12179763 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117447475-A | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-111511742-B | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| CN-1281433-A | Hydroxamic acid derivatives as matrix metalloproteinase (MMP) inhibitors | PFIZER LTD (US) | 2001-01-24 | — | — | CN | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-5346906-A | Enhancement of cholinergic transmitters in treatment of neurological and mental disorders such as Alzheimer's | MERCK SHARPE & DOHME LTD. (GB) | 1994-09-13 | — | — | US | disclosed |
| EP-0412798-A2 | Substituted pyridines, their preparation, formulations and use in dementia | MERCK SHARP & DOHME LTD. (GB) | 1991-02-13 | — | — | EP | disclosed |
| US-4713080-A | OXIDATIVE COLORING | WELLA AKTIENGESELLSCHAFT (DE) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | CHRNB2 59/4885CHRNA4 38/4885CYP11B1 595/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | CHRNB2 3913/4885CHRNA4 4001/4885CYP11B1 373/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CHRNB2 4885/4885CHRNA4 4875/4885CYP11B1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.